| Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are vital to normal and effective function of the brain and nervous system. Co. is developing a pipeline of product candidates derived from its NMDAr modulator discovery platform, or the discovery platform: NYX-2925 for the treatment of chronic pain; NYX-783 for the treatment of post-traumatic stress disorder; and NYX-458 for the treatment of cognitive impairment. We show 20 historical shares outstanding datapoints in our coverage of APTX's shares outstanding history.|
Understanding the changing numbers of APTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APTX by allowing them to research APTX shares outstanding history
as well as any other stock in our coverage universe.